

Miguel Regueiro

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6071802/publications.pdf>

Version: 2024-02-01

103
papers

4,467
citations

117571

34
h-index

110317

64
g-index

104
all docs

104
docs citations

104
times ranked

4380
citing authors

#	ARTICLE	IF	CITATIONS
1	Association of C-reactive Protein and Partial Mayo Score With Response to Tofacitinib Induction Therapy: Results From the Ulcerative Colitis Clinical Program. <i>Inflammatory Bowel Diseases</i> , 2023, 29, 51-61.	0.9	5
2	Rates of Intestinal Resection and Colectomy in Inflammatory Bowel Disease Patients After Initiation of Biologics: A Cohort Study. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e974-e983.	2.4	34
3	Brief Behavioral Therapy and Bupropion for Sleep and Fatigue in Young Adults With Crohn's Disease: An Exploratory Open Trial Study. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 96-104.	2.4	15
4	Trends and Outcomes of Acute Diverticulitis in Inflammatory Bowel Disease: A Propensity-matched National Study. <i>Inflammatory Bowel Diseases</i> , 2022, 28, 48-53.	0.9	2
5	Ileocolic Resection for Crohn Disease: The Influence of Different Surgical Techniques on Perioperative Outcomes, Recurrence Rates, and Endoscopic Surveillance. <i>Inflammatory Bowel Diseases</i> , 2022, 28, 289-298.	0.9	10
6	Real-World Effectiveness and Safety of Ustekinumab in Elderly Crohn's Disease Patients. <i>Digestive Diseases and Sciences</i> , 2022, 67, 3138-3147.	1.1	23
7	Proactive versus Reactive Therapeutic Drug Monitoring: Why, When, and How?. <i>Inflammatory Intestinal Diseases</i> , 2022, 7, 50-58.	0.8	24
8	Mesenteric Excision and Exclusion for Ileocolic Crohn's Disease: Feasibility and Safety of an Innovative, Combined Surgical Approach With Extended Mesenteric Excision and Kono-S Anastomosis. <i>Diseases of the Colon and Rectum</i> , 2022, 65, e5-e13.	0.7	16
9	Small Bowel Crohn's Disease Recurrence is Common After Total Proctocolectomy for Crohn's Colitis. <i>Diseases of the Colon and Rectum</i> , 2022, 65, 390-398.	0.7	3
10	Recommendations for Standardizing Clinical Trial Design and Endoscopic Assessment in Postoperative Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2022, 28, 1321-1331.	0.9	5
11	Rate and risk factors of postoperative endoscopic recurrence of moderate- to high-risk Crohn's disease patients - A real-world experience from a Middle Eastern cohort. <i>Saudi Journal of Gastroenterology</i> , 2022, .	0.5	4
12	Anorectal Strictures in Complex Perianal CD: How to Approach?. <i>Clinics in Colon and Rectal Surgery</i> , 2022, 35, 044-050.	0.5	2
13	Remestemcel-L allogeneic bone marrow-derived mesenchymal stem cell product to treat medically refractory Crohn's colitis: preliminary phase IB/IIA study. <i>British Journal of Surgery</i> , 2022, 109, 653-655.	0.1	3
14	Objective disease activity assessment and therapeutic drug monitoring prior to biologic therapy changes in routine inflammatory bowel disease clinical practice: TARGET-IBD. <i>BMC Gastroenterology</i> , 2022, 22, 71.	0.8	3
15	Venous Thromboembolism in Admitted Patients with Inflammatory Bowel Disease: An Enterprise-Wide Experience of 86,000 Hospital Encounters. <i>Diseases of the Colon and Rectum</i> , 2022, Publish Ahead of Print, .	0.7	3
16	Intra-abdominal septic complications after ileocolic resection increases risk for endoscopic and surgical postoperative Crohn's disease recurrence. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 1696-1705.	0.6	8
17	Lower Rates of Colorectal Cancer in Patients With Inflammatory Bowel Disease Using Anti-TNF Therapy. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 1052-1060.	0.9	37
18	Association Between Vedolizumab Levels, Anti-vedolizumab Antibodies, and Endoscopic Healing Index in a Large Population of Patients with Inflammatory Bowel Diseases. <i>Digestive Diseases and Sciences</i> , 2021, 66, 3563-3569.	1.1	3

#	ARTICLE	IF	CITATIONS
19	Tofacitinib Treatment Safety in Moderate to Severe Ulcerative Colitis: Comparison of Observational Population Cohort Data From the IBM MarketScan® Administrative Claims Database With Tofacitinib Trial Data. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 1394-1408.	0.9	20
20	Should We Be Screening for SARS-CoV-2 in IBD Patients Before Initiation of Biologic Therapy?. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 291-294.	0.9	2
21	Dysplastic Progression to Adenocarcinoma is Equivalent in Ulcerative Colitis and Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 24-34.	0.6	15
22	Postoperative outcomes after preoperative ustekinumab exposure in patients with Crohn's disease: a systematic review and meta-analysis. <i>Annals of Gastroenterology</i> , 2021, 34, 691-698.	0.4	5
23	Validated Indices for Histopathologic Activity Predict Development of Colorectal Neoplasia in Ulcerative Colitis. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 1481-1490.	0.6	3
24	Anal Squamous Cell Carcinoma in Ulcerative Colitis: Can Pouches Withstand Traditional Treatment Protocols?. <i>Diseases of the Colon and Rectum</i> , 2021, 64, 1106-1111.	0.7	3
25	Methodology and Initial Results From a Real-World Observational Cohort of Patients With Inflammatory Bowel Disease: TARGET-IBD. <i>Crohn's & Colitis 360</i> , 2021, 3, .	0.5	3
26	Patients With Inflammatory Bowel Disease on Treatment Have Lower Rates of Celiac Disease. <i>Inflammatory Bowel Diseases</i> , 2021, , .	0.9	6
27	The Fate of Unifocal Versus Multifocal Low-Grade Dysplasia at the Time of Colonoscopy in Patients with Inflammatory Bowel Disease. <i>Diseases of the Colon and Rectum</i> , 2021, Publish Ahead of Print, 1364-1373.	0.7	3
28	First or Second Biologic in Inflammatory Bowel Disease. <i>Journal of Clinical Gastroenterology</i> , 2021, Publish Ahead of Print, 740-746.	1.1	0
29	Gastrointestinal manifestations of COVID-19. <i>Cleveland Clinic Journal of Medicine</i> , 2021, , .	0.6	26
30	Inflammatory Bowel Disease Patients' Perspectives of Clinical Trials: A Global Quantitative and Qualitative Analysis. <i>Crohn's & Colitis 360</i> , 2021, 3, .	0.5	3
31	Effect of Telemedicine for Inflammatory Bowel Disease on Patient Activation and Self-Efficacy. <i>Digestive Diseases and Sciences</i> , 2020, 65, 96-103.	1.1	26
32	The Cost of Inflammatory Bowel Disease: An Initiative From the Crohn's & Colitis Foundation. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 1-10.	0.9	274
33	Perioperative and Postoperative Management of Patients With Crohn's Disease and Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1356-1366.	2.4	65
34	Shifting Cost-drivers of Health Care Expenditures in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 1268-1275.	0.9	23
35	Complete Resolution of Mucosal Neutrophils Associates With Improved Long-Term Clinical Outcomes of Patients With Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2510-2517.e5.	2.4	46
36	Listening to the Patient: Improving the Design and Conduct of Clinical Trials in Inflammatory Bowel Diseases. <i>Crohn's & Colitis 360</i> , 2020, 2, .	0.5	2

#	ARTICLE	IF	CITATIONS
37	International Organization for the Study of Inflammatory Bowel Disease: Global Strategies for Telemedicine and Inflammatory Bowel Diseases. <i>Journal of Crohn's and Colitis</i> , 2020, 14, S780-S784.	0.6	20
38	Development of Entrustable Professional Activities for Advanced Inflammatory Bowel Disease Fellowship Training in the United States. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 1291-1305.	0.9	2
39	Underwater versus conventional endoscopic mucosal resection for colorectal lesions: a systematic review and meta-analysis. <i>Endoscopy International Open</i> , 2020, 08, E1884-E1894.	0.9	18
40	Innovation in Inflammatory Bowel Disease Care During the COVID-19 Pandemic: Results of a Global Telemedicine Survey by the International Organization for the Study of Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2020, 159, 805-808.e1.	0.6	54
41	Safety and Efficacy of Bariatric Surgery in Inflammatory Bowel Disease Patients: a Systematic Review and Meta-analysis. <i>Obesity Surgery</i> , 2020, 30, 3872-3883.	1.1	25
42	TELEmedicine for Patients With Inflammatory Bowel Disease (TELE-IBD) Does Not Improve Depressive Symptoms or General Quality of Life Compared With Standard Care at Tertiary Referral Centers. <i>Crohn's & Colitis</i> 360, 2020, 2, otaa002.	0.5	15
43	Risks, time trends, and mortality of colonoscopy-induced perforation in hospitalized patients. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 1381-1386.	1.4	8
44	Gastrointestinal and hepatic manifestations of COVID-19: A comprehensive review. <i>World Journal of Gastroenterology</i> , 2020, 26, 2323-2331.	1.4	130
45	Hepatic manifestations of COVID-19. <i>Cleveland Clinic Journal of Medicine</i> , 2020, , .	0.6	7
46	COVID-19 in patients with IBD and pancreaticobiliary disorders. <i>Cleveland Clinic Journal of Medicine</i> , 2020, , .	0.6	4
47	Endoscopy in Postoperative Patients with Crohn's Disease or Ulcerative Colitis. Does It Translate to Better Outcomes?. <i>Gastrointestinal Endoscopy Clinics of North America</i> , 2019, 29, 487-514.	0.6	7
48	Biological Treatment and the Potential Risk of Adverse Postoperative Outcome in Patients With Inflammatory Bowel Disease: An Open-Source Expert Panel Review of the Current Literature and Future Perspectives. <i>Crohn's & Colitis</i> 360, 2019, 1, .	0.5	3
49	Extraintestinal Manifestations of Inflammatory Bowel Disease: Epidemiology, Etiopathogenesis, and Management. <i>Current Gastroenterology Reports</i> , 2019, 21, 31.	1.1	55
50	The Inflammatory Bowel Disease Medical Home: From Patients to Populations. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 1881-1885.	0.9	14
51	Three-Dimensional Nanoscale Nuclear Architecture Mapping of Rectal Biopsies Detects Colorectal Neoplasia in Patients with Inflammatory Bowel Disease. <i>Cancer Prevention Research</i> , 2019, 12, 527-538.	0.7	5
52	Editorial for Nancy Stoll's Article. <i>Crohn's & Colitis</i> 360, 2019, 1, .	0.5	0
53	Special Considerations for Colorectal Surgery in the Elderly IBD Patient. <i>Current Treatment Options in Gastroenterology</i> , 2019, 17, 449-456.	0.3	7
54	A Randomized Controlled Trial of TELEmedicine for Patients with Inflammatory Bowel Disease (TELE-IBD). <i>American Journal of Gastroenterology</i> , 2019, 114, 472-482.	0.2	108

#	ARTICLE	IF	CITATIONS
55	Value-Based Health Care in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 958-968.	0.9	13
56	Managing Risks with Biologics. <i>Current Gastroenterology Reports</i> , 2019, 21, 1.	1.1	50
57	A Practical Guide to the Safety and Monitoring of New IBD Therapies. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 831-842.	0.9	35
58	Ileocecal Anastomosis Type Significantly Influences Long-Term Functional Status, Quality of Life, and Healthcare Utilization in Postoperative Crohn's Disease Patients Independent of Inflammation Recurrence. <i>American Journal of Gastroenterology</i> , 2018, 113, 576-583.	0.2	40
59	Reduced Unplanned Care and Disease Activity and Increased Quality of Life After Patient Enrollment in an Inflammatory Bowel Disease Medical Home. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1777-1785.	2.4	63
60	Epithelioid Granulomas Associate With Increased Severity and Progression of Crohn's Disease, Based on 6-Year Follow-Up. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 900-907.e1.	2.4	26
61	Low Rates of Dermatologic Care and Skin Cancer Screening Among Inflammatory Bowel Disease Patients. <i>Digestive Diseases and Sciences</i> , 2018, 63, 2729-2739.	1.1	11
62	Knowledge Gaps in the Management of Postoperative Crohn's Disease: A US National Survey. <i>Digestive Diseases and Sciences</i> , 2018, 63, 53-60.	1.1	4
63	Inflammatory Bowel Disease Telemedicine Clinical Trial: Impact of Educational Text Messages on Disease-Specific Knowledge Over 1 Year. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 2191-2197.	0.9	18
64	Age Modifies the Association Between Depressive Symptoms and Adherence to Self-Testing With Telemedicine in Patients With Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 2648-2654.	0.9	8
65	The old versus the new: which do you keep in postoperative Crohn's disease?. <i>Intestinal Research</i> , 2018, 16, 319.	1.0	2
66	The Association Between Sustained Poor Quality of Life and Future Opioid Use in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 1380-1388.	0.9	31
67	Making a Medical Home for IBD Patients. <i>Current Gastroenterology Reports</i> , 2017, 19, 20.	1.1	18
68	Constructing an Inflammatory Bowel Disease Patient-Centered Medical Home. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 1148-1153.e4.	2.4	46
69	Peripheral Eosinophilia in Patients With Inflammatory Bowel Disease Defines an Aggressive Disease Phenotype. <i>American Journal of Gastroenterology</i> , 2017, 112, 1849-1858.	0.2	41
70	American Gastroenterological Association Institute Technical Review on the Management of Crohn's Disease After Surgical Resection. <i>Gastroenterology</i> , 2017, 152, 277-295.e3.	0.6	110
71	Etiology and Treatment of Pain and Psychosocial Issues in Patients With Inflammatory Bowel Diseases. <i>Gastroenterology</i> , 2017, 152, 430-439.e4.	0.6	104
72	Correlation of anemia status with worsening bowel damage as measured by Löfgren Index in patients with Crohn's disease. <i>Digestive and Liver Disease</i> , 2016, 48, 626-631.	0.4	9

#	ARTICLE	IF	CITATIONS
73	A Practical Approach to Preventing Postoperative Recurrence in Crohn's Disease. Current Gastroenterology Reports, 2016, 18, 25.	1.1	20
74	Group-Based Trajectory Modeling of Healthcare Financial Charges in Inflammatory Bowel Disease: A Comprehensive Phenotype. Clinical and Translational Gastroenterology, 2016, 7, e181.	1.3	14
75	A Pleiotropic Missense Variant in SLC39A8 Is Associated With Crohn's Disease and Human Gut Microbiome Composition. Gastroenterology, 2016, 151, 724-732.	0.6	109
76	Development of an Inflammatory Bowel Disease Research Registry Derived from Observational Electronic Health Record Data for Comprehensive Clinical Phenotyping. Digestive Diseases and Sciences, 2016, 61, 3236-3245.	1.1	28
77	Safety of Long-term Treatment With Certolizumab Pegol in Patients With Crohn's Disease, Based on a Pooled Analysis of Data From Clinical Trials. Clinical Gastroenterology and Hepatology, 2016, 14, 1753-1762.	2.4	14
78	Postoperative Medical Management of Crohn's Disease: Prevention and Surveillance Strategies. Journal of Gastrointestinal Surgery, 2016, 20, 1415-1420.	0.9	7
79	Association Between Long-Term Lipid Profiles and Disease Severity in a Large Cohort of Patients with Inflammatory Bowel Disease. Digestive Diseases and Sciences, 2016, 61, 865-871.	1.1	42
80	Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn's Disease After Ileocolonic Resection. Gastroenterology, 2016, 150, 1568-1578.	0.6	251
81	Association of Vitamin D Level With Clinical Status in Inflammatory Bowel Disease: A 5-Year Longitudinal Study. American Journal of Gastroenterology, 2016, 111, 712-719.	0.2	156
82	TELEmedicine for Patients with Inflammatory Bowel Disease (TELE-IBD): Design and implementation of randomized clinical trial. Contemporary Clinical Trials, 2015, 42, 132-144.	0.8	58
83	Persistent or Recurrent Anemia Is Associated With Severe and Disabling Inflammatory Bowel Disease. Clinical Gastroenterology and Hepatology, 2015, 13, 1760-1766.	2.4	62
84	Reply. Clinical Gastroenterology and Hepatology, 2014, 12, 1407.	2.4	1
85	Association Between Telephone Activity and Features of Patients With Inflammatory Bowel Disease. Clinical Gastroenterology and Hepatology, 2014, 12, 986-994.e1.	2.4	60
86	Reply. Clinical Gastroenterology and Hepatology, 2014, 12, 1764-1765.	2.4	0
87	Postoperative Therapy With Infliximab Prevents Long-term Crohn's Disease Recurrence. Clinical Gastroenterology and Hepatology, 2014, 12, 1494-1502.e1.	2.4	118
88	Postoperative Infliximab Is Not Associated with An Increase in Adverse Events in Crohn's Disease. Digestive Diseases and Sciences, 2011, 56, 3610-3615.	1.1	42
89	Crohn's disease activity index does not correlate with endoscopic recurrence one year after ileocolonic resection. Inflammatory Bowel Diseases, 2011, 17, 118-126.	0.9	125
90	Physician assessment of ulcerative colitis activity correlates poorly with endoscopic disease activity. Inflammatory Bowel Diseases, 2011, 17, 1008-1014.	0.9	36

#	ARTICLE	IF	CITATIONS
91	Response Friedman and Sparrow re: Stopping immunomodulators and biologics in inflammatory bowel disease patients in remission. Inflamm Bowel Dis 2011 [Epub ahead of print].. Inflammatory Bowel Diseases, 2011, 17, E163.	0.9	1
92	Management and prevention of postoperative Crohn's disease. Inflammatory Bowel Diseases, 2009, 15, 1583-1590.	0.9	46
93	Infliximab Prevents Crohn's Disease Recurrence After Ileal Resection. Gastroenterology, 2009, 136, 441-450.e1.	0.6	561
94	Preface. Gastroenterology Clinics of North America, 2009, 38, ix-x.	1.0	0
95	Infliximab dose intensification in Crohn's disease. Inflammatory Bowel Diseases, 2007, 13, 1093-1099.	0.9	119
96	Infliximab for Hospitalized Patients With Severe Ulcerative Colitis. Journal of Clinical Gastroenterology, 2006, 40, 476-481.	1.1	64
97	Medical management of left-sided ulcerative colitis and ulcerative proctitis: Critical evaluation of therapeutic trials. Inflammatory Bowel Diseases, 2006, 12, 979-994.	0.9	97
98	Clinical guidelines for the medical management of left-sided ulcerative colitis and ulcerative proctitis: Summary statement. Inflammatory Bowel Diseases, 2006, 12, 972-978.	0.9	59
99	Cigarette Smoking and Age at Diagnosis of Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2005, 11, 42-47.	0.9	52
100	Intravenous Cyclosporine in Severe Ulcerative Colitis: How Low Can You Go?. Inflammatory Bowel Diseases, 2004, 10, 170.	0.9	1
101	Treatment of Perianal Fistulizing Crohn's Disease with Infliximab Alone or as an Adjunct to Exam Under Anesthesia with Seton Placement. Inflammatory Bowel Diseases, 2003, 9, 98-103.	0.9	256
102	Infliximab for treatment of pyoderma gangrenosum associated with inflammatory bowel disease. American Journal of Gastroenterology, 2003, 98, 1821-1826.	0.2	209
103	The role of endoscopy in the evaluation of fistulizing Crohn's disease. Gastrointestinal Endoscopy Clinics of North America, 2002, 12, 621-633.	0.6	21